Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00349778 · OUTCOME

Overall Participant Survival (OS)

High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma · Source last updated 2017-12-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
5 years

What was measured

Survival status was assessed 5 years after transplant.

Groups in this outcome

High-Dose Sequential Therapy

Cyclophosphamide + etoposide + melphalan + carmustine with filgrastim

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
High-Dose Sequential Therapy102

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
High-Dose Sequential Therapy52Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        52
denoms
  1. counts
    1. group Id
      OG000
      value
      102
    units
    Participants
description
Survival status was assessed 5 years after transplant.
groups
  1. description
    Cyclophosphamide + etoposide + melphalan + carmustine with filgrastim
    id
    OG000
    title
    High-Dose Sequential Therapy
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
5 years
title
Overall Participant Survival (OS)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice